本帖最后由 老马 于 2013-3-13 13:43 编辑 & c( T. Y) ^4 k% N0 d
- q' t% f$ O) B! _! B# F* K+ r6 `+ a健择(吉西他滨)+顺铂+阿瓦斯汀
* {# H5 D7 `0 x/ N0 N# l% O: Q) I5 W Gemzar +Cisplatin + Avastin: Y% d2 _8 _6 p6 ^2 u
http://annonc.oxfordjournals.org/content/21/9/1804.full6 z0 w; `' `3 ]# f& q7 ?. w
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % H9 Z1 t' }$ M- P$ ^4 x( u' a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 q* y1 m9 T9 |) fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& [: }3 c- U* H$ n5 z) a( ?
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 616)
5 v$ X8 P- f9 A5 ~ U0 P华为网盘附件:, M3 N6 I I' g& Q
【华为网盘】ava.JPG& g( ~# Q9 Q/ a+ [$ Y% H" d" a
|